Physician profile
Helen Jackson
NPI 1063110849
$2,060.52
in general payments reported to CMS, 2019-2025
11 companies · $800 in 2025
The $800 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $644 · 2024: $617 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $590.27 | 2023-2024 | |
| Kyowa Kirin, INC. | $250.04 | 2025 | |
| Glaxosmithkline, LLC. | $241.17 | 2023 | Arexvy, Bexsero |
| Abbvie INC. | $224.82 | 2023-2025 | |
| Dexcom, INC. | $183.08 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $124.80 | 2025 | Zoryve |
| Gilead Sciences, INC. | $116.15 | 2025 | Epclusa |
| Axsome Therapeutics, INC. | $112.12 | 2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.26 | 2023 | |
| Boston Scientific Corporation | $25.82 | 2024 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.